Androgen Resistant Prostatic Cancer

Top drugs studied for this disease

All Approvals Safety alerts Label changes Trial results Research Guidance Withdrawals

CLINICAL_TRIALS trial_result · 2024-02-05
Clinical Trial Update: Efficacy Evaluation of VERU-111 for mCRPC in Patients Who Have Failed at Least One Androgen Receptor Targeting Agent [Phase 3]
Phase 3 trial evaluating VERU-111 for metastatic castration-resistant prostate cancer after AR-targeting therapy has been terminated.